Immunogenicity and Safety Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine GSK2340274A in Adults 18 to 64 Years of Age.

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine GSK2340274A in Adults 18 to 64 Years of Age.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Feb 2011 Actual end date (1 Oct 2010) added as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Actual initiation date (1 Apr 2010) added as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top